Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 2/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.31 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.31 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.31 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.31 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19209921 | 0.91 | SLC6A1 (0.35) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL20424217 | 0.85 | CHRM2 (0.35) | — | |
| SCHEMBL27654431 | 0.82 | ALDH1A1 (0.38) | — | |
| SCHEMBL7587103 | 0.79 | SLC6A1 (0.33) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL2905562 | 0.79 | SLC6A1 (0.33) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL28783768 | 0.79 | NAAA (0.41) | — | |
| SCHEMBL9438714 | 0.79 | — | — | |
| SCHEMBL7583693 | 0.78 | CHRNB2 (0.32) | — | |
| Hydrochloric Acid SCHEMBL8112201 | 0.78 | SLC6A1 (0.32) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| Hydrochloric Acid SCHEMBL7590833 | 0.78 | SLC6A1 (0.32) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11530198-B2 | Compositions and methods for treating infections | Vyera Pharmaceuticals, LLC (US) | 2022-12-20 | — | — | US | disclosed |
| US-20200407345-A1 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS | TURING PHARMACEUTICALS LLC | 2020-12-31 | — | — | US | disclosed |
| US-10774073-B2 | Compositions and methods for treating infections | Vyera Pharmaceuticals, LLC (US) | 2020-09-15 | — | — | US | disclosed |
| US-20200270233-A1 | DHFR INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO | Vyera Pharmaceuticals, LLC | 2020-08-27 | — | — | US | disclosed |
| EP-3665165-A1 | DHFR INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO | Vyera Pharmaceuticals, LLC (US) | 2020-06-17 | — | — | EP | disclosed |
| CN-111225908-A | DHFR inhibitors, compositions, and methods related thereto | 维耶拉制药有限责任公司 | 2020-06-02 | — | — | CN | disclosed |
| US-20190077794-A1 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS | Vyera Pharmaceuticals, LLC (US) | 2019-03-14 | — | — | US | disclosed |
| WO-2019032458-A1 | DHFR INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO | Vyera Pharmaceuticals, LLC (US) | 2019-02-14 | — | — | WO | disclosed |
| CN-109071486-A | Compositions and methods for treating infections | 维耶拉制药有限责任公司 | 2018-12-21 | — | — | CN | disclosed |
| EP-3411367-A1 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS | Vyera Pharmaceuticals, LLC (US) | 2018-12-12 | — | — | EP | disclosed |
| WO-2017136556-A1 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS | TURING PHARMACEUTICALS LLC (US) | 2017-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077794-A1 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS | DHFR, DHODH, QDPR | SLC6A1 3666/4885GABRA5 2492/4885GABRB2 2947/4885 |
| US-20200407345-A1 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS | DHFR, DHODH, QDPR | SLC6A1 3666/4885GABRA5 2492/4885GABRB2 2947/4885 |
| US-11530198-B2 | Compositions and methods for treating infections | DHFR, DHODH, QDPR | SLC6A1 3666/4885GABRA5 2492/4885GABRB2 2947/4885 |
| US-20200270233-A1 | DHFR INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO | DHFR, DHODH, FPGS | SLC6A1 2764/4885GABRA5 1688/4885GABRB2 2212/4885 |
| US-10774073-B2 | Compositions and methods for treating infections | DHFR, DHODH, QDPR | SLC6A1 3666/4885GABRA5 2492/4885GABRB2 2947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.